Adults 18 and older with obstructive sleep apnea (OSA) and overweight or obesity may qualify for a clinical study evaluating an investigational once-weekly medication designed to support weight reduction and improve sleep-related breathing.
Adults 18 and older with obstructive sleep apnea (OSA) and overweight or obesity may qualify for a clinical study evaluating an investigational once-weekly medication designed to support weight reduction and improve sleep-related breathing.
This research study is evaluating an investigational medication administered once weekly by injection, to determine whether it can help reduce body weight and improve OSA severity.
Researchers will compare the investigational medicine to a placebo* to assess its effects on breathing disruptions during sleep, weight loss, and overall health outcomes. The study will also evaluate the safety and tolerability of the investigational treatment.
Participants may receive study-related care, including lifestyle counseling focused on nutrition and physical activity, as well as regular monitoring throughout the study.
* A placebo is a “fake” treatment—such as a sugar pill, injection, or procedure—that contains no active medicine or therapeutic value. It is designed to look exactly like a real treatment but is used to test the effectiveness of an investigational medicine in research studies.
You may qualify if you:
Adults 18 and older with obstructive sleep apnea (OSA) and overweight or obesity may qualify for a clinical study evaluating […]
Rochester Clinical Research is seeking adults to participate in a research study evaluating an investigational medication for nerve pain caused […]
Adults 65 years and older may qualify for a study evaluating an investigational vaccine designed to help prevent C. difficile […]
Rochester Clinical Research is enrolling healthy adults ages 50–64 for a COVID-19 vaccine research study (non-mRNA). This study is enrolling […]
Rochester Clinical Research is currently enrolling adults for a research study evaluating a once-weekly injection for people with knee pain […]
Adults 18 to 80 years of age may qualify for a study evaluating an investigational treatment for irritable bowel syndrome […]